Actualités Alpha Cognition Inc - ACOG | Actions TSX Venture Exchange

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

Alpha Cognition Inc. (OTCQB: ACOG) (CSE: ACOG) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company developing novel therapeutics...

Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing...

Alpha Cognition Provides Private Placement Update

Not for distribution in the United States or to U.S. newswire services Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or...

Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing...

Alpha Cognition Announces Withdrawal of Marketed Public Offering

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VANCOUVER, British Columbia, Nov...

Alpha Cognition Announces Marketed Offering

NOT FOR DISSEMINATION IN THE UNITED STATESOR THROUGH U.S. NEWSWIRE SERVICES VANCOUVER, British Columbia, Nov...

Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing...

Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing...

Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing

NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing...

Alpha Cognition to Webcast Live at VirtualInvestorConferences.com June 23rd

VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB:...

Alpha Cognition Announces Successful Defense of European Patent Covering ALPHA-0602

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing...

Alpha Cognition Announces Positive Data from Pre-Clinical Studies and Discovery of GEM Combinations with Potential for Neurodegenerative Disease Treatment

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel...

Alpha Cognition Announces Grant of Stock Options

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing...

Alpha Cognition Announces First Quarter 2022 Results and Company Update

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Alpha Cognition Inc (ACOG)

Votre Hub pour des idées et discussions en direct en temps réel

ACOG Actualités

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Alpha Cognition Provides Private Placement Update

Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update

Alpha Cognition Announces Withdrawal of Marketed Public Offering

Alpha Cognition Announces Marketed Offering

Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update

Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease

Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing

Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease

Alpha Cognition to Webcast Live at VirtualInvestorConferences.com June 23rd

Alpha Cognition Announces Successful Defense of European Patent Covering ALPHA-0602

Alpha Cognition Announces Positive Data from Pre-Clinical Studies and Discovery of GEM Combinations with Potential for Neurodegenerative Disease Treatment

Alpha Cognition Announces Grant of Stock Options

Alpha Cognition Announces First Quarter 2022 Results and Company Update

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Alpha Cognition Inc (ACOG) Actualités

Alpha Cognition Inc (ACOG)

Votre Hub pour des idées et discussions en direct en temps réel

ACOG Actualités

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Alpha Cognition Provides Private Placement Update

Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update

Alpha Cognition Announces Withdrawal of Marketed Public Offering

Alpha Cognition Announces Marketed Offering

Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update

Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease

Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing

Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease

Alpha Cognition to Webcast Live at VirtualInvestorConferences.com June 23rd

Alpha Cognition Announces Successful Defense of European Patent Covering ALPHA-0602

Alpha Cognition Announces Positive Data from Pre-Clinical Studies and Discovery of GEM Combinations with Potential for Neurodegenerative Disease Treatment

Alpha Cognition Announces Grant of Stock Options

Alpha Cognition Announces First Quarter 2022 Results and Company Update

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités